Camzyos (mavacamten) — United Healthcare
obstructive hypertrophic cardiomyopathy (HCM) in adults with symptomatic New York Heart Association (NYHA) class II-III disease
Initial criteria
- Diagnosis of obstructive hypertrophic cardiomyopathy (HCM)
- Heart failure classified as New York Heart Association (NYHA) class II OR New York Heart Association (NYHA) class III
Reauthorization criteria
- Documentation of positive clinical response to Camzyos therapy
Approval duration
12 months